A Study of LAD106 in Healthy Adult Participants

← catalyst calendar

NCT07471932 · readout in 284 d

Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

93estimated

Sites

Country

Netherlands

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-02-17

actual

When the study began enrolling

Primary completion

2027-05-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-31

estimated

The whole study's end, after follow-up

First posted

2026-03-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Volunteers

Interventions

Drug: LAD106
Drug: Lebrikizumab — also filed as Ebglyss®
Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A (SAD): Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs

measured From start of study drug up to follow-up (Day 81)

Part B (MAD): Number of Participants with TEAEs and Severity of TEAEs

measured From start of study drug up to follow-up (Day 104)

Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed